Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1107-1112

  Hou, Ming Mo ^a,c   Huang, Shiu Feng ^b,c   Kuo, Han Pin ^a,c   Yang, Cheng T A ^a,c,d   Tsai, Ying Huang ^a,c   Yu, Chih Teng ^a,c   Lin, Horng Chyuan ^a,c   Chen, Chih Hung ^a,c   Wang, Chih Liang ^a,c,d   Chung, Fu Tsai ^a,c   Hsieh, Jia Juan ^a,c,e   Hsu, Todd ^e   Cheng, Hsin Yi ^a,c   Ou, Li Ying ^a,c   Wang, Hung Ming ^a,c   Lin, Yung Chang ^a,c   Chang, Nai Jen ^a,c   Chang, John Wen Cheng ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

Adenocarcinoma; Chromogenic in situ hybridization (CISH); EGFR; Erlotinib; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; FEMALE; GENE MUTATION; HUMAN; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84863345190     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E, Grimaldi GC, Roncalli M and Santoro A: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small cell lung cancer. Br J Cancer 91: 208-212, 2004. (Pubitemid 39037060)
2. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J and Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005. (Pubitemid 41058345)
3. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour S, Shepherd FA and Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21: Role of KRAS and EGFR as Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-4275, 2008.
4. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T and Tamura T: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 23: 6829-6837, 2005.
5. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr., Franklin WA, Crowley J and Gandara DR; Southwest Oncology Group: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23: 6838-6845, 2005.
6. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS and Haber DA: Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081-8092, 2005. (Pubitemid 46657411)
7. Chang JW, Liu -P, Hsieh M-H, Fang Y-F, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL and Huang SF: Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients. Lung Cancer 67: 328-339, 2008.
8. Huang, SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR and Tsai SF: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
9. Chou, TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF and Tsai CM: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757, 2005. (Pubitemid 40685592)
10. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005. (Pubitemid 47050841)
11. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ and Kim NK: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005. (Pubitemid 47050839)
12. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, Baek SM, Park CS, Park CM, Kim YI, Lim SC and Park KO: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11: 2244-2251, 2005.
13. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y and Nukiwa T: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-3346, 2006. (Pubitemid 46638887)
14. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N and Holloway B: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 24: 5034-5042, 2006. (Pubitemid 46631407)
15. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA and Bunn PA Jr.: Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small cell lung cancer patients treated with gefitinib. Ann Oncol 18: 752-760, 2007. (Pubitemid 46523281)
16. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregore V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr. and Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97: 643-655, 2005. (Pubitemid 40812628)
17. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA: Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807, 2005.
18. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA Jr, Varella-Garcia M, Danenberg KD and Hirsch FR: Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12: 3078-3084, 2006. (Pubitemid 43837354)
19. Yoo SB, Lee HJ, Park JO, Choe G, Chung DH, Seo JW and Chung JH: Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small cell lung carcinomas: a comparison with fluorescence in situ hybridization study. Lung Cancer 67: 301-305, 2010.
20. Simone G, Mangia A, Malfettone A, Rubini V, Siciliano M, Di Benedetto A, Terrenato I, Novelli F and Mottolese M: Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non-small cell lung carcinomas and lung metastases from colorectal cancer. J Exp Clin Cancer Res 29: 125-131, 2010.
21. Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA and Lindeman NI: EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 133: 922-934, 2010.
22. Daniele L, Macrì L, Schena M, Dongiovanni D, Bonello L, Armando E, Ciuffreda L, Bertetto O, Bussolati G and Sapino A: Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 6: 1223-1229, 2007. (Pubitemid 46711985)